Literature DB >> 10969350

Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections.

V Shanmugam1, W M Switzer, J N Nkengasong, G García-Lerma, T A Green, E Ekpini, M Sassan-Morokro, F Antunes, K Manshino, V Soriano, S Z Wiktor, W Heneine.   

Abstract

To explain the low transmissibility and pathogenicity of HIV-2 infection's plasma viral loads in both HIV-1- and HIV-2-infected persons were compared by using the polymerase chain reaction (PCR)-based Amp-RT assay to measure levels of reverse transcriptase (RT) activity. The study comprised a total of 155 HIV-infected-people including 58 who were infected with HIV-2 with CD4+ cell counts <500 x 106/L (n = 15), CD4+ cell counts >500 x 106/L (n = 26), or with tuberculosis (TB; n = 17), and 97 HIV-1-infected people with CD4+ cell counts <500 x 106/L (n = 32), CD4+ cell counts >500 x 106/L (n = 25), or TB (n = 40). Among persons with CD4+ cell counts <500 x 106/L, 11 (73.3%) of 15 HIV-2-infected persons had detectable plasma RT activity compared with 25 (78.1%) of 32 HIV-1-infected persons (p =.725). However, the median HIV-2 plasma RT activity in this group was significantly lower (2561 x 10-10 U/ml; p =.036; detectable range, 1712-644,868 x 10-10 U/ml) than the RT activity of HIV-1-infected persons with similar CD4+ cell counts (13,241 x 10-10 U/ml; detectable range, 8482-1,478,880 x 10-10 U/ml). Among TB patients, 10 (58.8%) of 17 HIV-2-infected persons had detectable plasma RT activity compared with 30 (75%) of 40 HIV-1-infected persons (p =.342). In contrast, among patients with CD4+ cell counts >500 x 106/L, none of 26 HIV-2-infected persons had detectable RT activity compared with 13 (52%) of 25 HIV-1-infected persons (p <.001). Our data suggest that unlike HIV-1 infection, HIV-2 infections with CD4+ cell counts >500 x 106/L are associated with a low level of viral replication, which may explain the longer clinical latency and lower transmissibility seen in HIV-2 infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969350     DOI: 10.1097/00126334-200007010-00011

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  8 in total

1.  Tracing the origin and history of the HIV-2 epidemic.

Authors:  Philippe Lemey; Oliver G Pybus; Bin Wang; Nitin K Saksena; Marco Salemi; Anne-Mieke Vandamme
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-12       Impact factor: 11.205

2.  Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is associated with high CD4+ T cell counts in viremic HIV-2 infection.

Authors:  Mohammad Khalid; Hangxing Yu; Daniel Sauter; Shariq M Usmani; Jan Schmokel; Jerome Feldman; Rob A Gruters; Marchina E van der Ende; Matthias Geyer; Sarah Rowland-Jones; Albert D Osterhaus; Frank Kirchhoff
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

3.  Human immunodeficiency virus (HIV)-2-specific T lymphocyte proliferative responses in HIV-2-infected and in HIV-2-exposed but uninfected individuals in Guinea-Bissau.

Authors:  S Andersson; O Larsen; Z Da Silva; H Linder; H Norrgren; F Dias; R Thorstensson; P Aaby; G Biberfeld
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

4.  In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

Authors:  Sherie Masse; Xiaozhi Lu; Tatyana Dekhtyar; Liangjun Lu; Gennadiy Koev; Feng Gao; Hongmei Mo; Dale Kempf; Barry Bernstein; George J Hanna; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

5.  Detection of simian immunodeficiency virus in diverse species and of human immunodeficiency virus Type 2 by using consensus primers within the pol region.

Authors:  Silvina Masciotra; Chunfu Yang; Danuta Pieniazek; Chanda Thomas; Sherry M Owen; Harold M McClure; Renu B Lal
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

6.  Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.

Authors:  Julia Drylewicz; Sophie Matheron; Estibaliz Lazaro; Florence Damond; Fabrice Bonnet; François Simon; François Dabis; Françoise Brun-Vezinet; Geneviève Chêne; Rodolphe Thiébaut
Journal:  AIDS       Date:  2008-02-19       Impact factor: 4.177

7.  The efficiency of Vpx-mediated SAMHD1 antagonism does not correlate with the potency of viral control in HIV-2-infected individuals.

Authors:  Hangxing Yu; Shariq M Usmani; Alexandra Borch; Julia Krämer; Christina M Stürzel; Mohammad Khalid; Xuehua Li; Daniela Krnavek; Marchina E van der Ende; Albert D Osterhaus; Rob A Gruters; Frank Kirchhoff
Journal:  Retrovirology       Date:  2013-03-05       Impact factor: 4.602

8.  High level of susceptibility to human TRIM5α conferred by HIV-2 capsid sequences.

Authors:  Junko S Takeuchi; Benjamin Perche; Julie Migraine; Séverine Mercier-Delarue; Diane Ponscarme; François Simon; François Clavel; Béatrice Labrosse
Journal:  Retrovirology       Date:  2013-05-06       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.